Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing doses of deupirfenidone were assessed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...

A locker room talk allowed senior forward Olivia Leuze and Cary-Grove to find their spark during Tuesday evening’s Fox Valley ...

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...

SALT LAKE CITY--(BUSINESS WIRE)--ClearOne (NASDAQ: CLRO), a global market leader in conferencing, collaboration, and network streaming solutions, today announced the appointment of FVC, a leading ...